passionately pursuing a better life for patients with cancer. follow our pursuit

latest news

ASCO 2020 TIVO-3 Presentation

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)

###